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factors for health care-associated acquisition
of MRSA; lack of resistance to non-β-lactam
antibiotics; frequent association with indige-
nous populations; and association with sub-
cutaneous abscess formation and necrotising
pneumonia. The latter clinical conditions








Objective:  To describe antimicrobial resistance and molecular epidemiology of 
methicillin-resistant Staphylococcus aureus (MRSA) isolated in community settings in 
Australia.
Design and setting:  Survey of S. aureus isolates collected prospectively Australia-wide 
between July 2004 and February 2005; results were compared with those of similar 
surveys conducted in 2000 and 2002.
Main outcome measures:  Up to 100 consecutive, unique clinical isolates of S. aureus 
 outpatient settings were collected at each of 22 teaching hospital and five private 
atories from cities in all Australian states and territories. They were characterised by 
icrobial susceptibilities (by agar dilution methods), coagulase gene typing, pulsed-
gel electrophoresis, multilocus sequence typing, SCCmec typing and polymerase 
 reaction tests for Panton–Valentine leukocidin (PVL) gene.
lts:  2652 S. aureus isolates were collected, of which 395 (14.9%) were MRSA. The 
er of community-associated MRSA (CA-MRSA) isolates rose from 4.7% (118/2498) of 
S. aureus isolates in 2000 to 7.3% (194/2652) in 2004 (P = 0.001). Of the three major CA-
MRSA strains, WA-1 constituted 45/257 (18%) of MRSA in 2000 and 64/395 (16%) in 2004 
(P = 0.89), while the Queensland (QLD) strain increased from 13/257 (5%) to 58/395 (15%) 
(P = 0.0004), and the south-west Pacific (SWP) strain decreased from 33/257 (13%) to 26/
395 (7%) (P = 0.01). PVL genes were detected in 90/195 (46%) of CA-MRSA strains, 
including 5/64 (8%) of WA-1, 56/58 (97%) of QLD, and 25/26 (96%) of SWP strains. 
Among health care-associated MRSA strains, all AUS-2 and AUS-3 isolates were 
multidrug-resistant, and UK EMRSA-15 isolates were resistant to ciprofloxacin and 
erythromycin (50%) or to ciprofloxacin alone (44%). Almost all (98%) of CA-MRSA 
strains were non-multiresistant.
Conclusions:  Community-onset MRSA continues to spread throughout Australia. 
The hypervirulence determinant PVL is often found in two of the most common 
CA-MRSA strains. The rapid changes in prevalence emphasise the importance of 
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ongoing surveillance.
For editorial comment, see page 374. See also pages 404 and 420he
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StaT  emergence of new hypervirulentains of methicillin-resistantphylococcus aureus (MRSA) caus-
ing moderate to severe community-acquired
infections is now a worldwide phenomenon.
Epidemics have been reported in Canada,1
the United States,2 and Europe.3 These
reports have a number of findings in com-
mon including: lack of association with risk
possession of the genes for Panton–Valen-
tine leukocidin (PVL), an extracellular toxin
that destroys leucocytes and causes tissue
necrosis.3,4
In Australia, non-multiresistant MRSA
associated with community infection
(CA-MRSA) was first observed in Western
Australia in the early 1990s, initially in
Indigenous people in remote communities,
and became known as WA-MRSA.5 Subse-
quently, other strains of CA-MRSA
appeared in WA. Infection caused by
CA-MRSA was first noted in the eastern
states in the mid-1990s.6 Studies in
Queensland7 and New South Wales8 ini-
t ially reported a strong association
between community-acquired infection
with non-multiresistant MRSA and Poly-
nesian background. The “south-west
Pacific” (SWP) strain of CA-MRSA causing
these infections was indistinguishable from
that reported previously in Auckland, New
Zealand,7,8 and was initially characterised
by the western Samoan phage typing pat-
tern. A second strain, the “QLD” strain, was
first identified in Queensland in 2000,
causing community-acquired infection in
people of European background.9
Both the SWP and QLD strains, but
not the WA strains, usually carry PVL
genes and are associated with abscess
formation, bacteraemia and necrotising
pneumonia.3,10,11 However, PVL genes
are carried on prophages, which are
capable of generating bacteriophages
(viruses that infect baceria) and conse-
quently have the potential to spread to
other strains of S. aureus.12
The epidemiology of community-onset
MRSA can be confusing. Because of the dif-
ferences in virulence, spectrum of infection
and antibiotic sensitivity patterns, it is impor-
tant to distinguish between infections caused
by MRSA strains circulating in the commu-
nity and not found in hospitals, and infec-
tions with onset in the community caused by
health care-associated strains (HA-MRSA).
The spread of the latter into the community is
well documented, although these strains do
not spread readily from person to person in
the community.13 The distinction between
these two types of acquisition is based on the
patient’s risk factors for health care acquisi-
tion, such as recent hospitalisation, surgery,
antibiotic medication, chronic medical condi-
tions, long-term care and health care occupa-
tional status.14 It is also possible to
discriminate between these epidemiologically
distinct strains by a variety of molecular
typing methods.
The Australian Group for Antimicrobial
Resistance (AGAR) previously established
that the predominant MRSA strains circulat-
ing in the community are WA-1, SWP and
QLD, which are now widely dispersed geo-
graphically.15 This report describes changes
in prevalence and geographic range of com-
munity-associated strains and the extent of
PVL gene carriage in community-associated
strains.MJA • Volume 184 Number 8 • 17 April 2006
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Survey method
Isolates were collected from patients attend-
ing primary care clinics, outpatient clinics,
emergency departments or other outpatient
settings, or residing in long-term residential
facilities. Twenty-two teaching hospital labo-
ratories and five private pathology laborato-
ries in nine Australian cities participated in
the study. Up to 100 consecutive clinical
isolates of S. aureus were collected at each
laboratory between 1 July 2004 and 8 Feb-
ruary 2005. Isolates from infection control
screening specimens were excluded, as were
duplicate clinical isolates, as determined by
antimicrobial susceptibility phenotype.
The results were compared with two pre-
vious similar surveys which used the same
isolate inclusion criteria and involved the
same laboratories, except that two fewer
teaching hospital laboratories participated
(one in Newcastle and one in Melbourne).15
Isolate characteristics
S. aureus was identified by standard meth-
ods, as described elsewhere.15 Susceptibility
testing was performed by agar dilution
according to Clinical Laboratory Standards
Institute methodology, using a single break-
point concentration of antimicrobial.16 Anti-
microbials were incorporated into agar
plates at the following concentrations: peni-
cillin G, 0.125 mg/L; oxacillin, 2 mg/L; van-
comycin, 2 mg/L; teicoplanin, 2 mg/L;
rifampicin, 1 mg/L; fusidic acid, 1 mg/L;
gentamicin, 4 mg/L; chloramphenicol, 8 mg/
L; erythromycin, 0.5 mg/L; clindamycin,
0.5 mg/L; tetracycline, 4 mg/L; trimetho-
prim, 8 mg/L; ciprofloxacin, 1 g/L; and
mupirocin, 1 mg/L. An antibiotic-free con-
trol plate and five control organisms were
included in each batch.15 Resistogram typ-
ing was performed by disk diffusion against
a panel of six chemicals and dyes, as previ-
ously described.15
Coagulase gene restriction fragment
length polymorphism typing was performed
as described elsewhere.15 Pulsed-field gel
electrophoresis (PFGE) of chromosomal
DNA was performed using the CHEF DR III
System (Bio-Rad Laboratories, Sydney,
NSW) and interpreted as described else-
where.15 Representative isolates were char-
acterised by multilocus sequence typing
(MLST) and staphylococcal chromosomal
cassette mec (SCCmec) typing (where mec is
the mobile genetic element responsible for
methicillin resistance, classifiable into five
major types), with results interpreted as
described previously.15
Strains are reported with their common
names (eg, WA-1) followed by the sequence
type (ST), methicillin resistance phenotype,
and SCCmec type (I to V) (eg, ST1-MRSA-IV).
Strains are classified into two groups on the
basis of previously published evidence: those
implicated in health care-associated infection
(HA-MRSA); and those implicated in commu-
nity-associated infection (CA-MRSA).15
CA-MRSA isolates were assayed for the
presence of PVL genes using polymerase chain
reaction (PCR) primers for a 1554-bp region
from lukS-PV and lukF-PV as follows: forward,
5´ GGCCTTTCCAATACAATATTGG 3´; and
reverse, 5´ CCCAATCAACTTCATAAATTG 3´.17
Statistical analysis
We determined the proportions of S.
aureus isolates which were considered CA-
MRSA and HA-MRSA in each surveillance
period and in each city, and also the
proportions of the six major HA-MRSA
and CA-MRSA strain types among all HA-
MRSA and CA-MRSA isolates, respec-
tively. Differences in proportions were
tested over the survey periods using the χ2
test for trend, where data were available
for all three survey periods, or a test for
the difference between two proportions,
where data were available for only two
survey periods. Differences were tested
between cities and within cities over the
survey periods. All tests for significance
were two-sided with α set at the 5% level
and were performed using Epi Info ver-
sion 6.0.4 (Centers for Disease Control
and Prevention, Atlanta, Ga, USA).
The survey did not require ethical
approval as all S. aureus isolates were from
routine diagnostic specimens referred to the
participating laboratories; information per-
taining to isolates was de-identified; and
there was no change to the routine process-
ing or reporting practices in the participat-
ing laboratories.
RESULTS
In the 2004 survey, we assessed 2652 iso-
lates of S. aureus, compared with 2486 in the
2000 survey, and 2488 in 2002. In 2004,
14.9% of isolates (395/2652) were resistant
to oxacillin (and therefore methicillin), com-
pared with 10.3% in 2000 (257/2498), and
15.2% in 2002 (363/2386).
The proportion of S. aureus isolates which
were HA-MRSA and CA-MRSA differed sig-
nificantly between the three surveys (P =
0.006 and P = 0.001, respectively; Box 1).
However, when analysed by city, HA-MRSA
proportions differed significantly between
surveys only in Darwin (P = 0.03).
1 Number of isolates of health care-associated and community-associated methicillin-resistant Staphylococcus aureus 
(MRSA) and percentage of all S. aureus isolates in participating Australian cities in 2000, 2002 and 2004
Staphylococcus aureus isolates Health care-associated isolates (HA-MRSA) Community-associated isolates (CA-MRSA)
City 2000 2002 2004 2000 2002 2004 P 2000 2002 2004 P
Perth 400 398 400 4 (1%) 13 (3%) 7 (2%) 0.45 40 (10%) 42 (11%) 44 (11%) 0.65
Darwin 99 100 59 1 (1%) 11 (11%) 5 (9%) 0.03 5 (5%) 10 (10%) 12 (20%) 0.003
Brisbane 300 300 300 6 (2%) 13 (4%) 12 (4%) 0.16 15 (5%) 20 (7%) 39 (13%) < 0.001
Sydney 700 689 699 85 (12%) 120 (17%) 100 (14%) 0.25 36 (5%) 46 (7%) 55 (8%) 0.04
Newcastle na na 96 na na 8 (8%) — na na 5 (5%) —
Canberra 100 100 100 0 5 (5%) 3 (3%) 0.09 4 (4%) 3 (3%) 2 (2%) 0.41
Adelaide 399 400 399 13 (3%) 11 (3%) 15 (4%) 0.69 12 (3%) 24 (6%) 26 (7%) 0.03
Hobart 100 100 99 0 1 (1%) 1 (1%) 0.38 2 (2%) 5 (5%) 2 (2%) 0.38
Melbourne 400 299 500 30 (8%) 34 (11%) 50 (10%) 0.23 4 (1%) 5 (2%) 9 (2%) 0.99
Total 2498 2386 2652 139 (5.6%) 208 (8.7%) 201 (7.6%) 0.006 118 (4.7%) 155 (6.5%) 194 (7.3%) 0.001
na = not available (no survey conducted). ◆MJA • Volume 184 Number 8 • 17 April 2006 385
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occurred over the same period in four cities:
Darwin (5% to 20%, P = 0.003), Brisbane
(5% to 13%, P < 0.0001), Sydney (5% to
8%, P = 0.04), and Adelaide (3% to 7%, P =
0.03). The total proportion of CA-MRSA
also increased significantly, from 4.7% in
2000 to 7.3% by 2004 (P = 0.001). In 2004,
CA-MRSA strains accounted for over 10% of
all clinical outpatient isolates of S. aureus in
Darwin, Brisbane and Perth. The proportion
of CA-MRSA strains in Melbourne and
Hobart remained lower than in other states
and did not increase significantly.
Community-associated strains
Three major strains of CA-MRSA predomi-
nated in all three surveys, with WA-1 (ST1-
MRSA-IV) consistently the most common
CA-MRSA strain (Box 2A). This strain is
isolated throughout the country, but repre-
sents a lower proportion of MRSA in the
eastern states than in the west. The propor-
tion of isolates that were strain WA-1 did
not change significantly over the three sur-
vey periods (P = 0.89).
The QLD strain (ST93-MRSA-IV) is now
the second most common CA-MRSA strain
and has increased significantly since 2000
(P = 0.0004), with a 1.5-fold increase as a
proportion of MRSA, and a fourfold increase
as a proportion of S. aureus by 2004. In
2004, this strain predominated in Brisbane
(35%) and Sydney (19%), and was found in
all other participating cities, except Mel-
bourne and Hobart.
The SWP strain (ST30-MRSA-IV) is the
third most common CA-MRSA strain. It
remained prominent in Brisbane, Sydney
and Darwin, but declined overall, from 13%
in 2000 to 7% by 2004 (P = 0.01).
In 2004, nine other CA-MRSA strains
were found: WA-2 (ST129-MRSA-IV), 19
isolates, predominantly in SA and WA);
WA-3 (ST5-MRSA-IV), 14, predominantly
in SA and WA; WA-12 (ST8-MRSA-IV), 4, in
Sydney and Brisbane; WA-15 (ST59-MRSA-
IV), 2, in Perth and Brisbane; WA-13
(ST584-MRSA-IV), 2, in Melbourne and
Brisbane; WA-23 (ST45-MRSA-IV), 2, in
Melbourne; WA-17 (ST583-MRSA-IV) and
WA-5 (ST8-MRSA-IV), 1 each in Sydney;
and WA-8 (ST75-MRSA-IV), 1, in Darwin.
Thus 12 strains of CA-MRSA carried SCC-
mec type IV in 2004, compared with four in
2000 and five in 2002.
Health care-associated strains
Among HA-MRSA strains, the proportion of
AUS-2 (subtype of ST239-MRSA-III)
decreased significantly over the three sur-
veys (P = 0.0003), while there was no signif-
icant trend for AUS-3 (also a subtype of
ST239-MRSA-III) (P = 0.46) (Box 2B). None
of the participating cities experienced a sig-
nificant change in the other major strain, UK
EMRSA-15 (ST22-MRSA-IV) over the three
survey periods, nor was there a significant
change overall (P = 0.17). Two isolates of
2 Number of isolates of the most common community-associated and health care-associated MRSA strains and percentage 
of all MRSA isolates in participating Australian cities in 2000, 2002 and 2004
A: Community-associated MRSA (CA-MRSA) strains*
B: Health care-associated MRSA (HA-MRSA) strains*
WA-1 (ST1) QLD (ST93) SWP (ST30)
City 2000 2002 2004 P 2000 2002 2004 P 2000 2002 2004 P
Perth 27 (61%) 22 (40%) 23 (45%) 0.13 0 1 (2%) 2 (4%) 0.95 0 1 (2%) 1 (2%) 0.95
Darwin 3 (50%) 2 (10%) 5 (29%) 0.79 0 0 2 (12%) — 0 5 (24%) 3 (18%) 0.95
Brisbane 3 (14%) 6 (18%) 7 (14%) 0.84 1 (5%) 3 (9%) 18 (35%) 0.001 9 (43%) 9 (27%) 9 (18%) 0.03
Sydney 4 (3%) 10 (6%) 5 (3%) 0.89 9 (7%) 26 (16%) 30 (19%) 0.02 20 (17%) 6 (4%) 13 (8%) 0.03
Newcastle na na 4 (31%) — na na 1 (8%) — na na 0 —
Canberra 0 0 0 — 1 (25%) 1 (13%) 2 (40%) 0.56 2 (50%) 2 (25%) 0 0.83
Adelaide 5 (20%) 14 (40%) 18 (44%) 0.06 1 (4%) 3 (9%) 3 (7%) 0.66 0 2 (6%) 0 —
Hobart 2 (100%) 3 (50%) 0 0.90 0 2 (33%) 0 — 0 0 0 —
Melbourne 1 (3%) 2 (5%) 2 (3%) 0.98 1 (3%) 0 0 — 2 (6%) 1 (3%) 0 0.90
National 45 (18%) 59 (16%) 64 (16%) 0.89 13 (5%) 36 (10%) 58 (15%) < 0.001 33 (13%) 26 (7%) 26 (7%) 0.01
* Strain common name and sequence type. na = not available (no survey conducted). 
AUS-2 (ST239) AUS-3 (ST239) UK EMRSA-15 (ST22)
City 2000 2002 2004 P 2000 2002 2004 P 2000 2002 2004 P
Perth 0 0 0 — 0 3 (6%) 0 — 3 (7%) 8 (15%) 6 (12%) 0.48
Darwin 0 8 (38%) 4 (24%) 0.34 1 (17%) 3 (14%) 1 (6%) 0.39 0 0 0 —
Brisbane 5 (24%) 9 (24%) 4 (8%) 0.04 0 3 (9%) 3 (6%) 0.90 1 (5%) 1 (3%) 5 (10%) 0.32
Sydney 61 (50%) 88 (53%) 57 (37%) 0.02 1 (0.8%) 2 (1%) 6 (4%) 0.05 23 (19%) 28 (17%) 37 (24%) 0.27
Newcastle na na 5 (39%) — na na 0 — na na 3 (23%) —
Canberra 0 5 (63%) 3 (60%) 0.62 0 0 0 — 0 0 0 —
Adelaide 2 (8%) 0 3 (7%) 0.71 8 (32%) 6 (17%) 5 (12%) 0.06 3 (12%) 5 (14%) 6 (15%) 0.48
Hobart 0 1 (17%) 0 — 0 0 1 (33%) — 0 0 0 —
Melbourne 22 (65%) 12 (31%) 14 (24%) < 0.001 8 (24%) 22 (56%) 31 (53%) 0.02 0 0 5 (9%) —
National 90 (35%) 123 (34%) 89 (23%) < 0.001 18 (7%) 47 (12%) 24 (6%) 0.46 30 (12%) 42 (12%) 62 (16%) 0.17
* Strain common name and sequence type. na = not available (no survey conducted). ◆386 MJA • Volume 184 Number 8 • 17 April 2006
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(ST36-MRSA-II) were also found in the
2004 survey.
Isolate characteristics
Antibiotic resistance phenotype differed
strikingly between HA-MRSA and CA-
MRSA. All AUS-2 and AUS-3 (HA-MRSA)
isolates were resistant to at least four non-β-
lactam antimicrobials: 86% were resistant to
the combination of gentamicin, erythromy-
cin and tetracycline; and only 4% were
sensitive to gentamicin. UK EMRSA-15 iso-
lates were usually resistant to ciprofloxacin
and erythromycin (50%) or ciprofloxacin
alone (44%), and differed from all other
MRSA isolates in being urease-negative
(with the exception of one WA-1 isolate
with no non-β-lactam resistance). On the
other hand, 60% of CA-MRSA isolates were
resistant only to β-lactams, and 29% were
resistant to only one other antimicrobial,
while 2% were resistant to more than three
non-β-lactams, and one isolate was resistant
to gentamicin.
The PVL gene was detected in 90 isolates
belonging to five CA-MRSA strains. The
proportion of PVL-positive isolates varied
markedly between strains (P < 0.0001): WA-
17, 1 (100%; 95% CI, 3%–100%); QLD, 56
(97%; 95% CI, 88%–100%); SWP, 25 (96%;
95% CI, 80%–100%); WA-12, 3 (75%; 95%
CI, 19%–99%); and WA-1, 5 (8%; 95% CI,
3%–17%). The proportion of PVL-positive
isolates also varied markedly between cities
(P < 0.0001): Canberra, 100%; Sydney,
80%; Brisbane, 74%; Darwin, 42%; New-
castle, 17%; Adelaide, 15%; Perth, 11%; and
Melbourne and Hobart, 0. Thirteen (14%)
of the PVL-positive isolates were resistant to
erythromycin.
DISCUSSION
The concurrent emergence and expansion of
multiple PVL-positive CA-MRSA clones on
different continents has been rapid and
striking. This epidemic has been very well
documented in Australia by AGAR: annual
studies conducted exclusively in teaching
hospitals from 1989 to 1999 showed that
non-multiresistant MRSA, a surrogate
marker for CA-MRSA, began to increase in
Perth in the early 1990s and in more easterly
cities in the late 1990s.10
The biennial studies reported here and
previously have established the major
strains causing community-onset MRSA
infection in Australia.15 Clearly, CA-MRSA
now represents a major clinical and public
health problem. The large distances between
Australian cities have been no barrier to the
rapid spread of the major epidemic strains,
WA-1, SWP and QLD. The first two of these
are pandemic strains which have appeared
on multiple continents.3,18,19 Demonstration
of the presence of the relatively small SCC-
mec type IV element (one of a range of
elements responsible for methicillin resist-
ance) in increasing numbers of lineages of S.
aureus is of great concern: this element is of
a size (about 28 kilobases) to allow spread
by bacteriophage transduction.
The increase in prevalence of CA-MRSA is
due to two mechanisms: first, clonal expan-
sion of successful lineages, such as the QLD
strain; and second, the transmission of SCC-
mec to an increasing number of lineages of S.
aureus. This raises the prospect of wide-
spread acquisition of methicillin resistance
in S. aureus, similar to the spread of penicil-
lin resistance seen in the latter half of the
20th century, which led to penicillin resist-
ance levels greater than 80%.10,20 Further-
more, the ability of CA-MRSA strains to
acquire resistance to other antimicrobials
will almost certainly pose a longer term
challenge. While only 2% of CA-MRSA iso-
lates were resistant to more than three non-
β-lactam antimicrobials in the 2004 survey,
no CA-MRSA isolates had that level of resist-
ance in the previous two surveys.
The spread of virulence genes is also a
potential problem. PVL genes are carried on
a prophage and so can be transmitted to
receptive strains by transduction.12 We
demonstrated the presence of PVL in five
CA-MRSA strains, three of which (WA-1,
QLD and SWP) are major epidemic strains.
PVL has been described in WA-1 only
recently,21,22 and clinical data on the associ-
ation of this strain with severe infections are
lacking. Nonetheless, it has recently been
suggested that drugs that shut down ribos-
omal translation of proteins in S. aureus,
such as clindamycin and linezolid, might
decrease production of toxins such as PVL.
Therefore, these drugs may be specifically
indicated in the treatment of serious CA-
MRSA infections.23 This hypothesis remains
to be tested in vivo.
As CA-MRSA strains are now common in
many parts of Australia, it is important that
doctors consider that any staphylococcal
infection — acquired in the community or
in hospital — may be caused by MRSA. It is
important to collect appropriate microbio-
logical specimens, such as swabs for local-
ised infections and blood cultures for
systemic infections, for culture and suscepti-
bility testing. Delay in recognition that these
infections are caused by MRSA can in turn
delay definitive treatment, and this may lead
to increased mortality or prolonged morbid-
ity.11,24 Laboratories need to expedite detec-
tion of MRSA, report sensitivity to an
appropriate range of non-β-lactam antibiot-
ics, and provide advice on suitable antimi-
crobials.
The choice of empirical treatment should
be guided by the severity of infection, the
presence of risk factors for HA-MRSA infec-
tion, and the local prevalence of CA-MRSA.
Where MRSA is likely, vancomycin is sug-
gested for cases of severe or life-threatening
infection, while linezolid may be considered
as a second-line agent.25
If infection is mild, it is still reasonable to
prescribe flu(di)cloxacillin (or alternative β-
lactams in cases of intolerance or allergy),
given that most strains of S. aureus are still
sensitive to β-lactams. However, should
MRSA be isolated, therapy should be
changed to an appropriate agent. A number
of readily available oral agents can be used
in mild to moderate infections. Clindamycin
has been suggested, but may not always be
appropriate because of the presence of
inducible resistance in some CA-MRSA
strains.25 Erythromycin is the best indicator
of this type of resistance in Australia, and we
found that 14% of PVL-positive CA-MRSA
isolates in this survey were resistant to
erythromycin. The use of tetracyclines such
as doxycycline is supported by a retrospec-
tive case series and case reports.26 Trimetho-
prim–sulfamethoxazole was found to be
equivalent to vancomycin in serious MRSA
infections in injecting drug users,27 and
there is also evidence of its success in less
serious community MRSA infections.28
Therefore, clindamycin, doxycycline or
trimethoprim–sulfamethoxazole may be
used for mild to moderate CA-MRSA infec-
tions, depending on susceptibility results.
However, tetracyclines should not be used
in children aged under 8 years, and trimeth-
oprim–sulfamethoxazole should not be used
in infants under 8 weeks. Ongoing surveil-
lance is essential to assess progress of the
epidemic of MRSA in the community in
Australia and changes in susceptibility of the
epidemic strains.
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